title: Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study.
abstract: BACKGROUND
  To asses the clinical profile, treatment outcome and prognostic factors in primary breast lymphoma (PBL).
  
  
  METHODS
  Between 1970 and 2000, 84 consecutive patients with PBL were treated in 20 institutions of the Rare Cancer Network. Forty-six patients had Ann Arbor stage IE, 33 stage IIE, 1 stage IIIE, 2 stage IVE and 2 an unknown stage. Twenty-one underwent a mastectomy, 39 conservative surgery and 23 biopsy; 51 received radiotherapy (RT) with (n = 37) or without (n = 14) chemotherapy. Median RT dose was 40 Gy (range 12-55 Gy).
  
  
  RESULTS
  Ten (12%) patients progressed locally and 43 (55%) had a systemic relapse. Central nervous system (CNS) was the site of relapse in 12 (14%) cases. The 5-yr overall survival, lymphoma-specific survival, disease-free survival and local control rates were 53%, 59%, 41% and 87% respectively. In the univariate analyses, favorable prognostic factors were early stage, conservative surgery, RT administration and combined modality treatment. Multivariate analysis showed that early stage and the use of RT were favorable prognostic factors.
  
  
  CONCLUSIONS
  The outcome of PBL is fair. Local control is excellent with RT or combined modality treatment but systemic relapses, including that in the CNS, occurs frequently.
authors.affiliation: Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon, CH-1011 Lausanne, Switzerland. wendy.jeanneret@chuv.ch
authors.forename: Wendy
authors.initials: W
authors.lastname: Jeanneret-Sozzi
authors.forename: Alphonse
authors.initials: A
authors.lastname: Taghian
authors.forename: Ron
authors.initials: R
authors.lastname: Epelbaum
authors.forename: Philip
authors.initials: P
authors.lastname: Poortmans
authors.forename: Daniel
authors.initials: D
authors.lastname: Zwahlen
authors.forename: Beat
authors.initials: B
authors.lastname: Amsler
authors.forename: Sylviane
authors.initials: S
authors.lastname: Villette
authors.forename: Yazid
authors.initials: Y
authors.lastname: Belkacémi
authors.forename: Tan
authors.initials: T
authors.lastname: Nguyen
authors.forename: Pierre
authors.initials: P
authors.lastname: Scalliet
authors.forename: Philippe
authors.initials: P
authors.lastname: Maingon
authors.forename: Cristina
authors.initials: C
authors.lastname: Gutiérrez
authors.forename: Pauline
authors.initials: P
authors.lastname: Gastelblum
authors.forename: Marco
authors.initials: M
authors.lastname: Krengli
authors.forename: Rita Abi
authors.initials: RA
authors.lastname: Raad
authors.forename: Mahmut
authors.initials: M
authors.lastname: Ozsahin
authors.forename: René-Olivier
authors.initials: RO
authors.lastname: Mirimanoff
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000401:mortality / Q000628:therapy*; D018567:Breast Neoplasms, Male / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008408:Mastectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D011878:Radiotherapy; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents